Investigational drug · Phase 2
DS-8201
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
84
Any phase or sponsor naming "DS-8201"
First trial start
2025
Sep 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DS-8201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Advanced Solid Tumor
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DS-8201" as an intervention, largest first.
- A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Pivotal-lookingActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT04622319 · 1,600 participants (planned) · Start Dec 4, 2020 · Primary completion Jul 2, 2025
Drug: DS-8201a; T-DM1 · For: HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer
Sites: Anaheim, California; Baldwin Park, California; Bellflower, California · 482 sites in all
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04784715 · 1,157 participants · Start Apr 26, 2021 · Primary completion May 3, 2027
Drug: Trastuzumab deruxtecan; Placebo and 3 more · For: Breast Cancer; HER2-positive; Metastatic
Sites: Tucson, Arizona; Springdale, Arkansas; Glendale, California · 283 sites in all
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05113251 · 927 participants · Start Oct 25, 2021 · Primary completion Mar 12, 2025
Drug: Trastuzumab Deruxtecan; Paclitaxel and 4 more · For: Breast Neoplasms; Breast Cancer; HER2-positive Early Breast Cancer
Sites: Springdale, Arkansas; Beverly Hills, California; Glendale, California · 145 sites in all
- Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04494425 · 866 participants · Start Jul 24, 2020 · Primary completion Mar 18, 2024
Drug: Trastuzumab deruxtecan; Capecitabine and 2 more · For: Advanced or Metastatic Breast Cancer
Sites: Scottsdale, Arizona; Springdale, Arkansas; Duarte, California · 293 sites in all
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06764875 · 840 participants (planned) · Start Mar 1, 2025 · Primary completion Apr 27, 2029
Drug: Rilvegostomig; Trastuzumab deruxtecan and 6 more · For: HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Anchorage, Alaska; Phoenix, Arizona; Duarte, California · 304 sites in all
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06731478 · 726 participants (planned) · Start Feb 27, 2025 · Primary completion Jun 1, 2028
Drug: Trastuzumab Deruxtecan; pembrolizumab and 2 more · For: Gastric Cancer; Gastroesophageal Junction Cancer
Sites: New Haven, Connecticut; Skokie, Illinois; Kansas City, Kansas · 250 sites in all
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06899126 · 686 participants (planned) · Start Oct 24, 2025 · Primary completion Apr 24, 2030
Drug: Trastuzumab Deruxtecan; pembrolizumab and 2 more · For: Non-small Cell Lung Cancer
Sites: Anchorage, Alaska; Fountain Valley, California; Los Angeles, California · 247 sites in all
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06467357 · 620 participants (planned) · Start Aug 12, 2024 · Primary completion Jun 12, 2028
Drug: Gemcitabine; Cisplatin and 3 more · For: Biliary Tract Cancer
Sites: Scottsdale, Arizona; Tucson, Arizona; Fullerton, California · 272 sites in all
- DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]Pivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT03523585 · 608 participants · Start Aug 1, 2018 · Primary completion Jun 30, 2022
Drug: Trastuzumab deruxtecan; Capecitabine and 2 more · For: Breast Cancer
Sites: Chandler, Arizona; Los Angeles, California; Monterey, California · 227 sites in all
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06989112 · 600 participants (planned) · Start Mar 27, 2025 · Primary completion Jan 19, 2029
Drug: Trastuzumab deruxtecan; Rilvegostomig and 4 more · For: Endometrial Cancer
Sites: Tucson, Arizona; Little Rock, Arkansas; Duarte, California · 256 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Personalized prediction of sequential therapeutic responses in HR+/HER2-low breast cancer using patient-derived organoids.
Zhao W, Wu Z, Li C, et al. · Transl Cancer Res 2026
- Case Report: Successful trastuzumab deruxtecan rechallenge after disease progression in a pretreated HER2-mutated lung adenocarcinoma patient.
Yan W, Liu C, Li T, et al. · Front Oncol 2026
- Dual Targeting of EGFR and HER2 by a Bispecific Antibody-Drug Conjugate Demonstrates Broad Antitumor Activity in Multiple Solid Tumors.
Chai X, Li F, Xie H, et al. · Mol Cancer Ther 2026
- Trastuzumab Deruxtecan as a Salvage Therapy after Disitamab Vedotin Failure in HER2 Altered Solid Tumors: A Preliminary Real-world Comparative Study.
Wang L, Lian X, Guo Q · Pak J Med Sci 2026
- HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade.
Li WJ, Kang KG, Zhang YX, et al. · Acta Pharmacol Sin 2026
- Novel anti-HER2 nanobody-drug conjugates with enhanced penetration of solid tumor and BBB, reduced systemic exposure and superior antitumor efficacy.
Wang Y, Liu L, Yang QY, et al. · Acta Pharmacol Sin 2026
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.